bioRxiv · 10.1101/2021.10.28.465226
A Potential Novel COVID-19 Vaccine With RBD-HR1/HR2 Hexamer Structure
Abstract
The COVID-19 pandemic and the continued spreading of the SARS-CoV-2 variants have brought a grave public health consequence and severely devastated the global economy with recessions. Vaccination is considered as one of the most promising and efficient methods to end the COVID-19 pandemic and mitigate the disease conditions if infected. Although a few vaccines have been developed with an unprecedented speed, scientists around the world are continuing pursuing the best possible vaccines with innovations. Comparing to the expensive mRNA vaccines and attenuated/inactivated SARS-CoV-2 vaccines, recombinant protein vaccines have certain advantages, including their safety (non-virus components), potential stronger immunogenicity, broader protection, ease of scaling-up production, reduced cost, etc. In this study, we reported a novel COVID-19 vaccine generated with RBD-HR1/HR2 hexamer that was creatively fused with the RBD domain and heptad repeat 1 (HR1) or heptad repeat 2 (HR2) to form a dumbbell-shaped hexamer to target the spike S1 subunit. The novel hexamer COVID-19 vaccine induced high titers of neutralizing antibody in mouse studies (>100,000), and further experiments also showed that the vaccine also induced an alternative antibody to the HR1 region, which probably alleviated the drop of immunogenicity from the frequent mutations of SARS-CoV-2.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, H., Gao, X., Wang, G., Zhang, J., Zhou, J., Wei, T., Zhang, Y., Liu, Y., Piao, J., Zhang, Q., Wang, Y., Ma, X., Zhu, X., Rao, Y., Xia, W., Xie, H., Zhang, W.. 2021-10-29. A Potential Novel COVID-19 Vaccine With RBD-HR1/HR2 Hexamer Structure. https://doi.org/10.1101/2021.10.28.465226
Cite the original work for its findings. Save a collection to share your selection of sources.